LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
P.A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Palmieri(University of Sassari), Mario Mandalà(University of Perugia), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Célèste Lebbé(Inserm), Ignacio Melero(University of Oxford), Maria Teresa Fierro(University of Turin), Virginia Ferraresi(Cancer Institute (WIA)), Antonio Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Evaristo Maiello(Casa Sollievo della Sofferenza), Hildur Helgadóttir(Karolinska University Hospital), Michele Guida(Istituto Tumori Bari), Paola Queirolo, Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Diana Giannarelli(Agostino Gemelli University Polyclinic), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich)
Cited by 30
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k